1-methoxycarbonyl-4-(4-fluorophenylcarbamoyl)piperazine | 283167-21-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-methoxycarbonyl-4-(4-fluorophenylcarbamoyl)piperazine
• 英文别名: Methyl 4-[(4-fluorophenyl)carbamoyl]piperazine-1-carboxylate
• CAS: 283167-21-5
• 化学式: C₁₃H₁₆FN₃O₃
• 分子量: 281.287
• InChiKey: DEIXSIXDZDQVDU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  61.9
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• Amide compounds
  申请人：Fujisawa Pharmaceutical Co. Ltd.

  公开号：US20040014745A1

  公开（公告）日：2004-01-22

  This invention relates to new amide compounds having the potentiation of the cholinergic activity, etc., and represented by general formula [I]. 1 wherein R 1 is acyl, R 2 is lower alkyl, etc., A is a single bond, 2 or —SO 2 —, E is lower alkylene, etc, X is CH or N, Y is a single bond, etc., Q is —CH 2 —, etc., and R 3 and R 4 are taken together to form lower alkylene, etc., and pharmaceutically acceptable salts thereof, to processes for preparation thereof and a pharmaceutical composition comprising the same.

  本发明涉及具有胆碱能活性增强作用的新酰胺化合物等，其通式为[I]。其中，R1为酰基，R2为较低的烷基等，A为单键，2或-SO2-，E为较低的亚烷基等，X为CH或N，Y为单键等，Q为-CH2-等，R3和R4结合形成较低的亚烷基等。本发明还涉及其药学上可接受的盐的制备方法以及包括它们的制药组合物。
• Agent for modulating excitatory synaptic transmission comprising a compound having alpha7 nicotinic acetylcholine receptor activation property
  申请人：——

  公开号：US20040092528A1

  公开（公告）日：2004-05-13

  The present invention relates to an agent for modulating excitatory synaptic transmission which contains a compound having &agr;7 nicotinic acetylcholine receptor activation property as an active ingredient, and the production of such an agent. It further relates to a pharmaceutical composition which contains such a compound together with a pharmaceutically acceptable carrier or excipient, and a method for modulating excitatory synaptic transmission which comprises administering such a composition. There is also provided a method for screening an agent for modulating excitatory synaptic transmission which comprises using &agr;7 nicotinic acetylcholine receptor activation property as an index. The present invention is useful for the prophylaxis and/or treatment of cerebral diseases, including dementia, amnesia, manic-depressive psychosis, schizophrenia, Parkinson's disease and psychosomatic disease.

  本发明涉及一种调节兴奋性突触传递的药剂，其含有具有α7尼古丁乙酰胆碱受体激活性质的化合物作为活性成分，以及制备该药剂的方法。它还涉及一种药物组合物，其中包含该化合物和药学上可接受的载体或赋形剂，以及一种调节兴奋性突触传递的方法，包括给予这样的组合物。还提供了一种用α7尼古丁乙酰胆碱受体激活性质作为指标的筛选调节兴奋性突触传递的药剂的方法。本发明对于预防和/或治疗包括痴呆症、遗忘症、躁郁症、精神分裂症、帕金森病和心身疾病在内的脑部疾病非常有用。
• AGENT FOR EXPRESSION OF LONG-TERM POTENTIATION OF SYNAPTIC TRANSMISSION COMPRISING COMPOUND HAVING BRAIN SOMATOSTATIN ACTIVATION PROPERTY
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：EP1235575A2

  公开（公告）日：2002-09-04
• AGENT FOR MODULATING EXCITATORY SYNAPTIC TRANSMISSION COMPRISING A COMPOUND HAVING ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATION PROPERTY
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：EP1315494A1

  公开（公告）日：2003-06-04
• US6710043B1
  申请人：——

  公开号：US6710043B1

  公开（公告）日：2004-03-23